Synergy Pharmaceuticals commences pivotal plecanatide CIC trial

|About: Synergy Pharmaceuticals, Inc. (SGYP)|By:, SA News Editor

Synergy Pharmaceuticals (SGYP +2.5%) initiates a Phase 3 pivotal trial of plecanatide in CIC. Primary endpoint: Proportion of patients who are overall responders.

The company is confident the GC-C agonist is "best-in-class."

Top-line data from an ongoing Phase 2b study of plecanatide in IBS-C is due in Q1 2014. (PR)